Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1285-1289

  Laidi, Fatna ^a   Bouziane, Amal ^b   Lakhdar, Amina ^c   Khabouze, Samira ^c   Rhrab, Brahim ^c   Zaoui, Fatima ^a  

^a Oral Biomechanics and Biotechnology research Unit   (Morocco)

^b Department of Periodontology Biostatistical clinical and epidemiological research laboratory ^*  (Morocco)

^c IBN SINA HOSPITAL   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER PATIENT; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL DEPARTMENT; HUMAN; METASTASIS; MOROCCO; RANK SUM TEST; SALIVA ANALYSIS; SALIVA LEVEL; STATISTICAL SIGNIFICANCE; TISSUE LEVEL;

EID: 84904308087     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S64230     Document Type: Article

References (38)

1. Coussens L, Yang-Feng TL, Lioa YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-1139.
2. Nunes RA, Harris LN. The HER-2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer. 2002;3(2):125-135.
3. Calzada V, Garcia F, Fernández M, et al. Labeling and biological evaluation of (99m)Tc-HYNIC-trastuzumab as a potential radiopharmaceutical for in vivo evaluation of HER2 expression in breast cancer. World J Nucl Med. 2013;12(1):27-32.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplifca- tion of the HER-2/neuoncogene. Science. 1987;235(4785):177-182.
5. Tsé C. Sher-2: a novel marker? Med Nucl. 2010;34(1):66-71. French.
6. Pellikainen J, Naukkarinen A, Ropponen K, et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer. 2004;40(10):1485-1495.
7. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330(18):1260-1266.
8. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
9. Belkacemi Y, Gligorov J, Mauriac L, Azria D. HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)? Bull Cancer. 2006;93(10):991-999.
10. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER-2 targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269-280.
11. Sauter G, Lee J, Barlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27(8):1323-1333.
12. McIntyre R, Bigler L, Dellinger T, Pfeifer M, Mannery T, Streckfus C. Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(6):687-690.
13. Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res. 2000;6(6):2363-2370.
14. Kong Y, Dai S, Xie X, et al. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012;138(2):275-284.
15. Di Gioia D, Dresse M, Mayr D, et al. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta. 2014;430:86-91.
16. Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007;9(5):1-8.
17. Dako. HercepTest working procedure, 18th edition. 2013. Available from: http://www.dako.com/dist/download.pdf?objectid=120856006. Accessed June 6, 2014.
18. Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res. 1982;61(10):1158-1162.
19. Nogourani MC, Janghorbani M, Isfahan RK, Beheshti MH. Effects of chewing different favored gums on salivary flow rate and pH. Int J Dent. 2012;2012:569327.
20. Krishnaswamy U, Balachandran P, Rajakumar I, Balachandar K, Mansoor M. Correlation of HER-2 neu over-expression with clinico- pathological features of carcinoma breast. Apollo Med. 2013;10(4): 313-317.
21. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2): 142-153.
22. Mostafa NA, Eissa SS, Belal DM, Shoman SH. Assessment of Her-2/ neu gene amplifcation status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining. J Egypt Natl Canc Inst. 2011;23(1): 41-46.
23. Badzek S, Kelovic VL, Plestina S, Humar I, Veir Z, Mihaljevic Z. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off? Wien Klin Wochenschr. 2011;123(23-24):726-731.
24. Leyland-Jones B, Smith BS. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol. 2011;12(3):286-295.
25. Köstler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(5):1618-1624.
26. Müller V, Witzel I, Lück HJ, et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2004;86(1):9-18.
27. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 2000;6(6):2356-2362.
28. Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunochemistry and fuorescence in situ hybridization and with response rate. Ann Oncol. 2005;16(2):234-239.
29. Kong SY, Nam BH, Lee KS, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem. 2006;52(8):1510-1515.
30. Tse C, Brault D, Gligorov J, et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem. 2005;51(7):1093-1101.
31. Krainer M, Brodowicz T, Zellinger R, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology. 1997;54(6):475-481.
32. Al Kawas S, Rahim ZH, Ferguson DB. Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol. 2012;57(1):1-9.
33. Lamster IB, Ahlo JK. Analysis of gingival crevicular fuid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci. 2007;1098:216-229.
34. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006;137(3):313-321.
35. Lac G. Intérêt et champs d'application des dosages salivaires [Relevance and usefulness of saliva assays]. Sci Sports. 1998;13:55-63. French.
36. Hofman LF. Human saliva as a diagnostic specimen. J Nutr. 2001;131(5):1621S-1625S.
37. Bernardes VF, Gleber-Netto FO, Sousa SF, Silva TA, Aguiar MC. Clinical signifcance of EGFR, Her-2 and EGF in oral squamous cell car- cinoma: a case control study. J Exp Clin Cancer Res. 2010;29(40):1-7.
38. Pardis S, Sardari Y, Ashraf MJ, et al. Evaluation of tissue expression and salivary levels of HER2/neu in patients with head and neck squamous cell carcinoma. Iran J Otorhinolaryngol. 2012;24(69):161-170.